Anacetrapib and dalcetrapib: Two novel cholesteryl ester transfer protein inhibitors

Annals of Pharmacotherapy

Volumn 45, Issue 1, 2011, Pages 84-94

  Miyares, Marta A ^a  

^a JACKSON MEMORIAL HOSPITAL   (United States)

Author keywords

Anacetrapib; Cardiovascular disease; Cholesteryl ester transfer protein; Dalcetrapib; Dyslipidemia

Indexed keywords

ANACETRAPIB; ATORVASTATIN; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; DALCETRAPIB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETOCONAZOLE; MIDAZOLAM; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL;

AREA UNDER THE CURVE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CARDIOVASCULAR SYMPTOM; CHOLESTEROL TRANSPORT; CONSTIPATION; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; DYSPEPSIA; FLATULENCE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IC 50; ISCHEMIC HEART DISEASE; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; MULTICENTER STUDY (TOPIC); MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; SIDE EFFECT; SINGLE DRUG DOSE;

ANIMALS; CARDIOVASCULAR DISEASES; CHOLESTEROL ESTER TRANSFER PROTEINS; DRUG INTERACTIONS; DYSLIPIDEMIAS; HUMANS; LIPID REGULATING AGENTS; OXAZOLIDINONES; SULFHYDRYL COMPOUNDS;

EID: 78751482905     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P446     Document Type: Article

References (52)

1. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. Highdensity lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-14.
2. Jacobs DR (for Lipid Research Clinics Follow-up Study). High-density lipoprotein cholesterol and coronary heart disease, cardiovascular disease, and all-cause mortality (abstract 737). Circulation 1985;72(suppl III):185.
3. Watkins LO, Neaton JD, Kuller LH. Racial differences in high-density lipoprotein cholesterol and coronary heart disease incidence in the usualcare group of the Multiple Risk Factor Intervention Trial. Am J Cardiol 1986;57:538-45.
4. Miller NE, Thelle DS, Forde OH, Mjos OD. The Tromso Heart-Study. High-density lipoprotein and coronary heart-disease: a prospective casecontrol study. Lancet 1977;1:965-8.
5. Goldbourt U, Medalie JH. High density lipoprotein cholesterol and incidence of coronary heart disease-the Israeli Ischemic Heart Disease Study. Am J Epidemiol 1979;109:296-308.
6. Enger SC, Hjermann I, Foss OP, et al. High density lipoprotein cholesterol and myocardial infarction or sudden coronary death: a prospective casecontrol study in middle-aged men of the Oslo study. Artery 1979;5:170-81.
7. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996;124 (suppl):11S-20S.
8. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15.
9. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001;285:1585-91. DOI 10.1001/jama.285.12.1585
10. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart study. Implications for treatment. Circulation 1992;85:37-45.
11. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55. DOI 10.1016/S0735-1097(86)80293-5
12. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995;345:1274-5.
13. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97. DOI 10.1001/jama.285.19.2486
14. Sacks FM, Tonkin AM, Shepherd J, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 2000;102:1893-900.
15. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357: 1301-10.
16. Birjmohun R, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2005;45:185-97. DOI 10.1016/j.jacc.2004.10.031 (Pubitemid 40094724)
17. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res 1993;34: 1255-74.
18. Clark RW, Sutfin TA, Ruggeri RB, et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 2004; 24:490-7. DOI 10.1161/01.ATV.0000118278.21719.17 (Pubitemid 38326143)
19. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004;350:1505-15.
20. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22. DOI 10.1056/NEJMoa0706628 (Pubitemid 350146106)
21. Vergeer M, Stroes ES. The pharmacology and off-target effects of some cholesterol estertransfer protein inhibitors. Am J Cardiol 2009;104(suppl): 32E-8E. DOI 10.1016/j.amjcard.2009.09.017
22. Toth PP. Reverse cholesterol transport: high-density lipoprotein's magnificent mile. Curr Atheroscler Rep 2003;5:386-93.
23. Wang M, Briggs MR. HDL: the metabolism, function, and therapeutic importance. Chem Rev 2004;104:119-37.
24. Chapman MJ. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol Ther 2006;111: 893-908. DOI 10.1016/j.pharmthera.2006.02.003 (Pubitemid 44164383)
25. Shah PK. Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease. Eur Heart J 2007;28:5-12. DOI 10.1093/eurheartj/ehl392 (Pubitemid 46134950)
26. Schwartz CC, VandenBroek JM, Cooper PS. Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J Lipid Res 2004;45:1594-607. DOI 10.1194/jlr.M300511-JLR200 (Pubitemid 39296198)
27. de Grooth GJ, Klerkx AH, Stroes ES, Stalenhoef AF, Kastelein JJ, Kuivenhoven JA. A review of CETP and its relation to atherosclerosis. J Lipid Res 2004;45:1967-74. DOI 10.1194/jlr.R400007-JLR200 (Pubitemid 40990890)
28. Krauss RM. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol 1994;5:339-49.
29. Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993;94:350-6.
30. Ranalletta M, Bierilo KK, Chen Y, et al. Biochemical characterization of cholesteryl ester transfer protein inhibitors. J Lipid Res 2010;51:2739-52. DOI 10.1194/jlr.M007468
31. Tan EY, Hartmann G, Chen Q, et al. Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys. Drug Metab Dispos 2010;38:459-73. DOI 10.1124/dmd.109.028696
32. Krishna R, Garg A, Panebianco D, et al. Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol 2009; 68:535-45.
33. Krishna R, Bergman AJ, Jin B, et al. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Clin Pharmacol Ther 2008; 84:679-83. DOI 10.1038/clpt.2008.109
34. Kumar S, Tan EY, Hartmann G, et al. Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans. Drug Metab Dispos 2010;38:474-83. DOI 10.1124/dmd.109.028704
35. Krishna R, Anderson MS, Bergman AJ, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase 1 studies. Lancet 2007;370:1907-14.
36. Clark RW, Ruggeri RB, Cunningham D, Bamberger MJ. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res 2006;47:537-52. DOI 10.1194/jlr.M500349-JLR200 (Pubitemid 43345595)
37. Krishna R, Bergman AJ, Jin B, et al. Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers. J Clin Pharmacol 2009;49:80-7. DOI 10.1177/0091270008326718
38. Krishna R, Garg A, Jin B, et al. Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol 2009;67:520-6. DOI 10.1111/j.1365-2125.2009.03385.x
39. Phelan M, Kuhlmann O, Anzures-Cabrera, J, Matharu B, Bentley D. Effect of hepatic impairment on the pharmacokinetics of dalcetrapib (abstract 135). J Clin Lipidol 2010;4:215-6.
40. Okamoto H, Iwamoto Y, Maki M, Sotani T, Yonemori F, Wakitani K. Effect of JTT-705 on cholesteryl ester transfer protein and plasma lipid levels in normolipidemic animals. Eur J Pharmacol 2003;466:147-54. DOI 10.1016/S0014-2999(03)01548-6 (Pubitemid 36385100)
41. Bisoendial RJ, Hovingh GK, El Harchaoui K, et al. Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia. Arterioscler Thromb Vasc Biol 2005;25:e133-4.
42. Stein EA, Roth EM, Rhyne JM, Burgess T, Kallend D, Robinson JG. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. Eur Heart J 2010;31:480-8. DOI 10.1093/eurheartj/ehp394
43. de Grooth GJ, Kuivenhoven JA, Stalenhoef AFH, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans. A randomized phase II dose-response study. Circulation 2002;105:2159-65. DOI 10.1161/01.CIR.0000015857.31889.7B (Pubitemid 34517159)
44. Derks M, Abt M, Phelan M, et al. Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug-drug interactions. J Clin Pharmacol 2010;50:1188-201. DOI 10.1177/0091270009358709
45. Derks M, Fowler S, Kuhlmann O. In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates. Curr Med Res Opin 2009;25:891-902.
46. Derks M, Fowler S, Kuhlmann O. A single-center, open-label, one sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the s-methyl metabolite of dalcetrapib. Clin Ther 2009;31: 586-99. DOI 10.1016/j.clinthera.2009.02.011
47. Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J 2009;157:352-60. DOI 10.1016/j.ahj.2008.09.022
48. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010;363: 2406-15. DOI 10.1056/NEJMoa1009744
49. Kuivenhoven JA, de Grooth GJ, Kawamura H, et al. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 2005;95:1085-8. DOI 10.1016/j.amjcard.2004.12.064 (Pubitemid 40544314)
50. Schwartz GG, Olsson AG, Ballantyne CM, et al. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 2009;158:896-901. DOI 10.1016/j.ahj.2009.09. 017
51. Stein EA, Stroes ES, Steiner G, et al. Safety and tolerability of dalcetrapib. Am J Cardiol 2009;104:82-91. DOI 10.1016/j.amjcard.2009.02.061
52. Derks M, Abt M, Mwangi A, Meneses-Lorente G. Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing. Eur J Clin Pharmacol 2010;66:775-83. DOI 10.1007/s00228-010-0841-2